Ke laʻa Forsig - nā ʻōlelo aʻoaʻo no ka hoʻohana ʻana, nā loiloi, nā analogie maʻalahi

Hāʻawi kēia ʻaoʻao i ka papa inoa o nā hui āpau o Forsig i ka hoʻonohonohoʻana a me nā hōʻike no ka hoʻohana. ʻO kahi papa inoa o nā analogue maʻalahi, a hiki iāʻoe ke hoʻohālikelike i nā kumukūʻai i nā lāʻau lapaʻau.

• ʻO ka mea maʻalahi loa o Forsig:Invokana
• ʻO ka punahele kaulana loa ʻo Forsig:Jardin
• Hoʻolaha ATX: Dapagliflozin
• Nā mea waiwai / pilikino: dapagliflozin
  

I ke helu ʻana i ke kumukūʻai analogie o Forsig a ʻo ke kumukūʻai haʻahaʻa i loaʻa ma nā papa kumukūʻai i hāʻawi ʻia e nā lāʻau lapaʻau i lawe ʻia i ka mooolelo

Hāʻawi ʻia papa inoa o nā lāʻau lapaʻau kahua o nā helu helu o nā lāʻau lapa i noi nui ʻia

Nā kuʻuna i ka hoʻonohonoho ʻana a me nā hōʻike no ka hoʻohana

ʻO ka papa inoa ma luna o nā mea hoʻohālikelike lapaʻau, e hōʻike ana Nā koho Forsig, kūpono loa ia no ka mea ua like lākou me ka like o nā mea hana a me ke kūleʻa e like me ke kuhikuhi ʻana no ka hoʻohana

Nā kumuhana ma o ka hōʻike ʻana a me ke ʻano o ka hoʻohana ʻana

ʻO ka ʻike nui, mea kikoʻī, hoʻopuka puka

ʻO kēia manawa hou, kahi papa hou o nā lāʻau lapaʻau me nā waiwai hoʻohaʻahaʻa i ka hilahila, akā ke loaʻa kahi hopena pilikino hoʻohālikelike i nā lāʻau lapaʻau i hoʻohana mua ʻia, ua loaʻa ma Rusia. ʻO kekahi o nā mea mua ma ka ʻāina i hoʻopaʻa ʻia ka lāʻau lapaʻau Forsig.

Hōʻike ʻia ka lāʻau lapaʻau i loko o ka pūnaehana radar (hoʻopaʻa inoa i ka lāʻau) ma ke ʻano he hypoglycemic lāʻau i manaʻo ʻia no ka hoʻohana waha.

Hiki i nā mea loea i ke aʻo ʻana ke loaʻa nā hopena hoihoi, e hōʻoia ana i ka hōʻemi ʻana i ka loaʻa ʻana o ka hopena o nā lāʻau lapaʻau i lawe ʻia a kāpae paha i kekahi o nā hihia o ka insulin ma muli o ka hoʻohana ʻana i kahi lāʻau hou.

Hoʻohālikelike ʻia nā loiloi o nā endocrinologists a me nā mea maʻi ma kēia ʻano. Nui ka ʻoliʻoli i nā manawa hou, a makaʻu kekahi iā lākou ke hoʻohana nei, e kali ana i ka ʻike e pili ana i nā hopena o ka hoʻohana lōʻihi.

Loaʻa ka lāʻau lapaʻau i ke ʻano o nā papa i loaʻa ka nui o 10 a 5 mg a i kīpī i nā poli ma ka nui o 10, me 14 mau ʻāpana.

Aia kēlā me kēia papa i kahi Dapagliflozin, ʻo ia ka mea hana nui.

E loaʻa nā mea hoihoi i kēia mau ʻōhua:

• mikuleka
• lactose anhydrous,
• silika
• crospovidone
• paʻahau magnesium.

• hoʻokaʻawale ʻokoʻa polyvinyl alakani (Opadry II ʻomaele),
• titanium hone
• macrogol
• ka leʻaleʻa talcum
• kaʻaole hao kaona ʻaila.

Ka hana lāʻau lapaʻau

ʻO Dapagliflozin, e hana nei i ka mea ikaika o ka lāʻau lapaʻau, ʻo ia hoʻi ka mea paʻa o SGLT2 (nā protein), ʻo ia hoʻi, ke kāpae nei i kā lākou hana. Ma lalo o ke ʻano o nā mea lapaʻau, ua hoʻemi ʻia ka nui o ka glucose mai ka urine mua, no laila, e hoʻokō piha ʻia kāna excretion ma muli o ka hana o nā keiki.

Ke alakaʻi nei kēia i kahi kaila o ka glycemia koko. ʻO kahi hiʻohiʻona hoʻohanohano o ka lāʻau lapaʻau kona koho kiʻekiʻe nui, ma muli o ka mea e pili ʻole ai i ka lawe ʻana o ka glucose i nā ʻāpana a ʻaʻole hoʻi e pōʻino i kona komo ʻana i ka wā e komo ai ia i loko o kahi ʻāpana.

Kuhi ka hopena nui o ka lāʻau i ka hoʻohemo ʻana e nā ʻōpū o ka glucose, kahi i hoʻopaʻa ʻia i ke koko. Hoʻā pinepine pinepine ʻia ke kino kanaka i nā huahana metabolic a me nā meaʻala.

Mahalo i ka hana i hoʻokūpaʻa ʻia o nā keiki, ua hoʻomoʻi ʻia kēia mau mea a me ka ʻimi pū ʻia me ka urine. Ma ke kaʻina o ka ʻōpio, hele nā ​​koko i nā manawa he nui ma o ka glomeruli renal. Hoʻomai ʻia nā mea kanu pono i loko o ke kino, a ua kānana ʻia nā koena a pau, ka hoʻokumu ʻana i ka urine mua. ʻO kona nui o kēlā me kēia lā hiki ke 10 mauha.

Ke hoʻololi i kēia wai i ka urine a komo i kahi ʻāpana, pono e hoʻonui ʻia kāna ʻohi. Loaʻa kēia pahuhopu e ka hoʻohuli ʻana i loko o ke koko o nā mea pono āpau, me ka glucose.

Ke hana ʻole nei i ka patology, a hoʻihoʻi hou ʻia nā mea a pau, akā me ka maʻi hakahaka he hapa hapa o ke kō i loko o ka hapa. Loaʻa kēia i ka pae glycemia ma mua o 9-10 mmol / L.

ʻO ka lawe ʻana i ka lāʻau lapaʻau i loko o kahi palā helu nui e hoʻolaha i ka hoʻokuʻu ʻana a hiki i 80 g o ka glucose koko i loko o ka urine. ʻAʻole hilinaʻi kēia hapa nui i ka nui o ka insulin i hana ʻia e ka pancreas a i loaʻa mai e ka maʻi ʻana.

Hoʻomaka ka wehe ʻana o ka maʻi glucose ma hope o ka lawe ʻana i ka pōpoki, a mau ʻia kona hopena no 24 mau hola. ʻAʻole ikaika ka mea ikaika o ka lāʻau i ka hana kūlohelohe o ka kūlohelohe o ka endogenous glucose i ka wā e hele ai ka hypoglycemia.

I nā hopena o nā hoʻokolohua, ua hōʻike ʻia ka holomua o ka hana i nā cell beta e kuleana no ka hana ʻana o ka hormone. I ka poʻe maʻi i lawe i ka lāʻau lapaʻau ma ke ʻano o 10 mg no 2 mau makahiki, ua hoʻopiʻi ʻia ka glucose, e alakaʻi ana i ka nui o ka diuresis osmotic. Hiki ke hoʻonui ʻia i ka nui o ka urine me ka piʻi nui o ka sodium excretion ma o nā keiki, akā ʻaʻole i hoʻololi i ka waiwai o ke kumu serum o kēia waiwai.

Hoʻohana ka hoʻohana ʻana o Forsigi i kahi hāʻule o ke koko i hiki ke aneʻi ma nā hebedoma 2-4 ma hope o ka hoʻomaka ʻana o ka hoʻokele. Eia kekahi, ʻo ka hoʻohanaʻana i ka lāʻau no 3 mau mahina e hōʻemi i ka hemoglobin glycosylated.

Lapaʻau lāʻau

Hoʻohālikelike ka hopena pharmacokinetic e nā hiʻohiʻona o ka hili, hoʻoulu, ka metabolism a me ka excretion o nā mea nui:

1. Hoʻopau Ma hope o ke komo ʻana, ua hoʻopiha piha ʻia nā ʻāpana o nā māka e nā pā o ka ʻāpana gastrointestinal (gastrointestinal tract), ʻaʻohe o ka manawa ʻai. ʻO ke kauā nui loa ma hope o ka lawe ʻana i kahi ʻōpū ʻole e hōʻea ma hope o 2 mau hola a hoʻonui i ka hapa me ka dosis. ʻO ka pae o ka bioavailability piha o ka mea nui ka 78%.
2. Kahele. ʻO ka mea hana o ka lāʻau lapaʻau e aneane 91% pili i nā protein. ʻAʻole pilikia ka maʻi o nā palaka a me nā palaka alima i kēia hōʻailona.
3. Hāpai. ʻO ka mea nui o ka lāʻau ka hopena o ka glucoside me ka lālona a carbon me ka glucose, e wehewehe ana i kona kūʻē i nā glucosidases. ʻO ka hapalua ola e koi no ka hapalua o nā ola o nā mea lapaʻau mai ka plasma koko he 12.9 mau hola ma ka pūʻulu noiʻi o nā mea hana olakino maikaʻi.
4. ʻĀina. Hoʻopiliʻia nā māhele o ka lāʻau lapaʻau ma o nā keiki.

Kūleʻa wikiō ma ke ala o Forsig, ʻāpana 1:

Nā hōʻailona a me nā contraindications

ʻAʻole hiki i ka lāʻau lapaʻau e hoʻomaʻamaʻa i ka glycemia inā hoʻomau ka hoʻomau i ka hoʻomau ʻana mai i ka lilo ʻana o nā pale.

ʻO ia ke kumu o ka mālamaʻaiʻai ʻana i ka meaʻai a me ka hoʻokō ʻana i kekahi mau hana kino ponoʻawaʻī e pono ke kaʻina hana therapeutic mandala. ʻO Forsig e hiki ke kau ʻia ma ke ʻano he lāʻau lapaʻau nona wale nō, akā ʻo ka mea maʻamau ke hāʻawi ʻia nei kēia mau papa i hui pū ʻia me Metformin.

• ka kaumaha o ke kaumaha me nā non-insulin-hilinaʻi,
• hoʻohana e like me kahi lāʻau lapaʻau hou i nā maʻi me ka maʻi maʻi maʻi kino,
• hoʻoponopono ʻana i nā maʻi maʻamau o ka hana.
• ka heleʻana o nā papa e pāpā i ka hana kino.

1. ʻO ka maʻi maʻi kāpeka.
2. Kahawai Hoʻākāka ka Contraindication ma ka hapa ʻole o ka ʻike e hōʻike ana i ka palekana o ka hoʻohana i kēia manawa.
3. Lactation wā.
4. He makahiki 75 a keu. ʻO kēia ma muli o ka emi ʻana o nā hana i hana ʻia e nā keiki, a me ke kahe ʻana o ka nui o ke koko.
5. Lolino lactose, kahi mea i hoʻohui ʻia i nā papa.
6. Hiki i kahi maʻi āpau ke hoʻomohala i ka wā e hoʻohana ʻia nā mea kolo i loko o ka pūpū o kahi pākaukau.
7. E hoʻonui i ke kiʻekiʻe o nā kino ketone.
8. ʻĀpanaanane (diabetes).
9. ʻO ka ʻae ʻana i kekahi diuretics, ka hopena o ka mea i hoʻonui ʻia me ka therapy wāwahi me nā papa Forsig.

• nā maʻi maʻamau
• inu wai, Nikotine (ʻaʻohe hōʻike no ka hopena o ka lāʻau i lawe ʻia)
• hematocrit,
• maʻi maʻi ʻōnaehana
• elemakule
• hanaʻino ʻino
• puʻuwai paʻakikī.

Nā ʻōkuhi no ka hoʻohana

Lawe ʻia nā papa pākuʻi i loko o kahi waihona i hilinaʻi ʻia i ka lāʻau i hāʻawi ʻia i ka mea maʻi:

1. Monotherapy. ʻAʻole pono ka nui o ka dosage i ka 10 mg i kēlā me kēia lā.
2. Hoʻohui paʻa. I ka lā, ua ʻae ʻia e lawe i 10 mg o Forsigi i ka hui pū me Metformin.
3. Initial therapy me 500 mg o Metformin he 10 mg (hoʻokahi i ka lā).

ʻAʻole hoʻokele ʻia ka lawelawe ʻana i ka lāʻau i ka manawa e ʻai ai i ka meaʻai. ʻO ka hōʻemi ʻana i ka nui o ka lāʻau e noi pinepine pinepine ʻia me ka maʻi insulin a i ʻole nā ​​lāʻau lapaʻau e hoʻonui ai i kāna hilo.

ʻO nā maʻi me ka maʻi koʻikoʻi o ke akeʻa a maʻa paha ka hoʻomaka ʻana e hoʻomaka i ka lawe ʻana i nā papa me ka nui o ka 5 mg. I ka wā e hiki mai ana, hiki ke hoʻonui ʻia i 10 mg, ke hoʻolako ʻia e hoʻomau maikaʻi ʻia nā ʻāpana.

Kūleʻa wikiō ma ke ala o Forsig, ʻāpana 2:

ʻO nā maʻi maʻi kūikawā

Hiki i nā hiʻohiʻona o nā lāʻau lapaʻau ke ʻano me kekahi mau ala o ka mea maʻi a i ʻole nā ​​hiʻohiʻona:

1. Nā kuʻuna o nā keiki. ʻO ka nui o ka glucose i hoʻopuka pololei ʻia ma ka hana ʻana o kēia mau ʻano.
2. I kahi hihia o ka hōʻino i loko o ka kō, ua loli iki ka hopena o ka lāʻau lapaʻau, no laila, ʻaʻole pono ke hoʻoponopono ʻia o nā ʻano palapala i ʻōlelo ʻia. ʻO nā kūleʻa nui loa i nā hiʻohiʻona o ka mea hana pono ke nānā wale ʻia me kahi koʻikoʻi koʻikoʻi o nā patology.
3. Makau. ʻAʻole hōʻike nā mea maʻi ma lalo o ka 70 mau makahiki i ka nui o ka hoʻolaha.
4. Kakauolelo I ka wā o ka lāʻau lapaʻau, uaʻoi aku ka wahine ma mua o ka AUC ma ka 22% hoʻohālikelike ʻia me nā kāne.
5. ʻAʻole pili nā pili i rasacial i nā ʻokoʻa ʻē i ka ʻike ka systemic.
6. Ke kaumaha. ʻOi aku ka nui o nā mea maʻi ma lalo o nā waiwai i ka wā o ka hopena.

ʻAʻole i aʻo ʻia ka hopena o ka lāʻau i nā keiki, no laila ʻaʻole pono e hoʻohana ʻia me he ʻano lā no ka maʻi. Ua pili kēia palena no ka wahine hapai a me ka lactating, no ka mea ʻaʻohe ʻike e pili ana i ke komo ʻana o nā mea waiwai i ka waiū.

Nā ʻōlelo kikoʻī

Loaʻa ka hopena o ka lāʻau i ka hiki ʻana o nā maʻi e pili ana i ka maʻi maʻi ma ka mea maʻi:

1. Nā kuʻuna o nā keiki. I ka nui o nā hihia, ʻae ʻia ka hopena o ka hoʻohana ʻana i ka lāʻau i ka poʻe e hōʻeha nei i nā maʻi malpunc organ. I nā hopena koʻikoʻi o ka pathology, ʻaʻole lawe i nā papa e alakaʻi i ka hopena therapeutic e makemake ʻia. Hōʻike kēia mau ʻōlelo i ka pono no ka mālama pinepine ʻana i nā hana hula, pono e hoʻokau ʻia i kekahi mau manawa i ka makahiki e like me nā ʻōlelo loea.
2. Halawai o ke akea. Me kēlā mau hōʻino, e hoʻonui ʻia ka ʻike o ka ʻenehana ikaika i ʻāpana o ka lāʻau lapaʻau.

ʻO ke kumu Forsig e alakaʻi i nā loli aʻe:

• hoʻonui i ka pilikia o ka hoʻohaʻahaʻa i ka nui o ke koko kahe,
• hoʻonui i ka puʻuwai o ke ala i loko o ke kaomi,
• ea hou i ka kaulike electrolyte,
• hoʻonui ka hopena o ka hoʻomohala ʻana e pili ana i ka wahi o ka urinary
• Hiki i ke ketoacidosis,
• hoʻonui i ka hematocrit.

He mea nui e hoʻomaopopo e pono e lawe i nā papa ma hope o ke kamaʻilio me ke kauka.

Nā hopena ʻaoʻao a me ka overdose

Manaʻo ʻia ʻo Dapagliflozin i kahi mālama palekana a i ka manawa hoʻokahi o nā papa ʻaina, ʻoi aku ka nui o ka nui o ka mea i ae ʻia ma o 50 mau manawa, ua ʻae maikaʻi ʻia.

Ua nānā ʻia ka hoʻonā ʻana i ka wai o ka glucose i nā lā he nui, akā ʻaʻole i ʻike ʻia nā hihia o ka maloʻo, me ka hypotension a me ka nānāʻole ʻana o ka electrolyte.

I nā hui ʻikepili, kahi i lawe ai kekahi poʻe iā Forsig a ua lawe kekahi i ka placebo, ka loaʻa ʻana o ka hypoglycemia, a me nā mea ʻino ʻē aʻe.

ʻO ka hōʻemi ʻana i nā maʻi pono e mālama ʻia i loko o kēia mau hanana:

• ua hoʻonui ʻia ka hana
• Aia kekahi ʻano like ʻole e pili ana i ka pāpē,
• puka hou
• hoʻohele ʻoe
• ua hana ka ʻili o ka ʻili
• i hoʻomohala ʻia nā kaʻina pili

Inā ʻike ʻia kahi overdose, pono ia i mālama ʻia i ka mālama ʻana i ka mālama pono.

Hiki iaʻu ke lilo i ka momona me Forsiga?

I nā ʻōlelo kuhikuhi no ka lāʻau lapaʻau, hōʻike ka mea hana i ka nui o ke kaumaha i mālama ʻia i ka wā o ka lāʻau lapaʻau. Kūpono nui ʻia kēia ma nā maʻi e loaʻa wale ana mai ka maʻi maʻi maʻi, akā, ʻoiai hoʻi mai ka momona.

Ma muli o nā waiwai diuretic, hōʻemi ka lāʻau i ka nui o ke kahe i loko o ke kino. ʻO ka hiki i nā lāʻau lapaʻau e hoʻopili i kahi ʻāpana o ka glucose ka mea e kōkua ai i ka nalowale o nā paona keu.

ʻO nā kumu nui no ka hoʻokō ʻana i ka hopena o ka hoʻohana ʻana i ka lāʻau, ʻaʻole lawa ka kīnā a me ka hoʻopuka ʻana i nā mea paʻa i ka meaʻai e like me ka meaʻai i makemake ʻia.

ʻAʻole pono nā kānaka olakino e hoʻohana i kēia mau palaka no ka hoʻolilo kaumaha. ʻO kēia no ka nui o ka ukana i hoʻopuka ʻia ma luna o nā kau, a me ka ʻike i ka hiki me ka hoʻohana ʻana iā Forsigi.

Nā Kūleʻa Kūʻai a me nā Analog

Kōkua ka lāʻau lapaʻau e hoʻoikaika i ka diuretics, insulin a me nā lāʻau lapaʻau e hoʻonui ai i kāna hilo.

Hoʻomaopopo ka maikaʻi o ka lāʻau lapaʻau i ka wā e lawe nei i ka lāʻau lapaʻau e hiki mai ana:

• Rifampicin,
• Kakau Nua
• enzyme e paipai ana i ka hoʻokūkū o nā meaʻokoʻa'ē aʻe.

Ke hoʻonui nei ka hoʻonui ʻana i ka papa Forsig a me ka waikawa mefenamic i ka hoʻolaha ʻana o ka ʻōnaehana o ka mea ikaika e 55%.

Ua manaʻo ʻia ʻo Forsiga ʻO ka lāʻau lapaʻau wale nō ka loaʻa iā Dapagliflozin i loaʻa ma Rusia. ʻO nā mea hou aʻe, nā huahana analog e like me nā mea mua.

Hiki i kahi papa no nā papa Forsig hiki i nā lāʻau lapaʻau glyphosine:

Hoʻohui o nā poʻe loea a me nā maʻi

Mai nā loiloi o nā kauka a me nā mea maʻi e pili ana i ka lāʻau Forsig, hiki iā mākou ke manaʻo e hōʻemi ka lāʻau lapaʻau i ka glucose i loko o ke koko a loaʻa kahi hopena maikaʻi loa i ke kino ma ke ʻano he nui nō naʻe, eia kekahi mau mea ʻokoʻa ikaika, pono e noʻonoʻo i ka wā e lawe ai i ka lāʻau.

Ua hōʻike ʻia ka lāʻau lapaʻau i kona pono i ka holo ʻana o nā hoʻokolohua. Hiki ke hoʻokō i nā glycemia i ka hapa nui o ka hopena me ka loaʻa ʻole o nā hopena hopena. Ke hoʻomau nei kekahi mau mea maʻi i ka hoʻonāʻauʻana i ka insulin. Lawe ʻia kēia ʻikepili mai nā hualoaʻa o kahi hoʻokolohua ma kahi o 50,000 poʻe me ka glycemia mai 10 mmol / l i komo. Ma kahi o ka hoʻokūpaʻa ʻana i nā pae gula, ua loaʻa ka lāʻau i ka hopena maikaʻi i ka olakino holoʻokoʻa.

ʻO Alexander Petrovich, ʻo ka endocrinologist

ʻO Forsyga ka lāʻau lapaʻau mua ma ka pūʻulu o kahi papa hou o ka pale aku. ʻAʻole hilinaʻi nā mea o ka lāʻau i ka hana o nā beta beta, me ka insulin. Hoʻopuka ka mau lālā i ka reabsorption o ka glucose i loko o nā keiki, ma laila e hōʻemi ai i nā waiwai i loko o ke koko.ʻO nā pōmaikaʻi kūpono loa ka hiki ke hoʻemi i ke kaumaha o ke kino a hōʻemi i ka hopena o ka hypoglycemia. Ua hōʻike ʻia nā hoʻokolohua lāʻau like ʻole me ka pili ʻole o ka hopena me nā hopena ʻaoʻao. Ua hana maikaʻi ʻia ka lāʻau lapaʻau ma waho o nā makahiki he nui, kahi mau ia i hōʻoia hou ai i kona pono.

Irina Pavlovna, ʻo ka endocrinologist

Ua kuhikuhi ʻia nā papa Forsig i koʻu makuahine ma hope o ka hōʻole ʻana o kāna i ka insulin. I ka manawa o ka hoʻomakaʻana o kahi hoʻokomo, aneane loa nā hōʻailona āpau o koʻu makuahine i kahi maʻamau. ʻO ka C-peptide ma lalo o ka palena i ʻāpono ʻia, a me nā kō, ʻo ke kumu, ʻo ia hoʻi ma kahi o 20. Ma kahi o 4 mau lā ma hope o ka papa mua, ua ʻike ʻia nā hoʻomaikaʻi. Ua kāpae ka Sugar ma luna o 10, ʻoiai me nā kaʻe mau ʻana o nā lāʻau ʻē aʻe (Amaril, Siofor). Ma hope o hoʻokahi mahina o ka mālama ʻana i kēia mau lāʻau, ua hoʻopau ʻia nā lāʻau he nui no ka makuahine. Hiki iaʻu ke ʻōlelo inā ʻoiai ke ala o Forsig ua ʻoluʻolu loa.

Heluhelu wau i nā loiloi mai nā mea hoʻohana ʻē aʻe a kahaha nui. Ua kōkua ka lāʻau lapaʻau i nā mea he nui, akā ʻaʻole iaʻu. Mai ka hoʻomaka ʻana o kāna hana, ʻaʻole i hoʻi hou kaʻu mau honi i ka maʻamau, akā ua piʻi pū kekahi. Akā ʻo ka mea ʻoi loa, ʻo ka minamina ia i ʻike ʻia i loko o ke kino holoʻokoʻa, ʻaʻole hiki ke ʻae ʻia. Ke manaʻo nei au, ʻaʻole pono e hoʻohana ʻia kahi lāʻau me nā hopena like ʻole.

ʻO ke kumu o kahi kāʻei Forsig o nā papa 30 (10 mg) kahi he 2600 rubles.

Ka ʻokoʻa like, hiki ke pili pū i ka hōʻike a me ke ʻano o ka noi

Pehea e ʻike ai i kahi analogue ʻano maʻalahi o kahi lāʻau lapaʻau nui?

No ka ʻike ʻana i kahi analogue kūʻai like ʻole i ka lāʻau lapaʻau, kahi generic a i ʻole synonymation, ʻo ka mea mua mua mākou i manaʻo no ka hoʻolohe ʻana i ka hoʻopili ʻana, ʻo ia nā ʻano like ʻole o nā mea kaha a me nā hōʻailona no ka hoʻohana. Hōʻike ka mea like ʻole o ka lāʻau lapaʻau me ka lapaʻau a like pū me ka lāʻau lapaʻau, kūloko a me ka mea pono i ʻole nā ​​lāʻau lapaʻau. Eia naʻe, mai poina e pili ana i nā māhele like ʻole o nā lāʻau like like, hiki ke pili i ka palekana a me ka hana. Mai poina e pili ana i nā kauoha a nā kauka, hiki i ka lāʻau lapaʻau ponoʻī ke hōʻeha i kou olakino, no laila e ʻōlelo mau i kāu kauka ma mua o ka hoʻohana ʻana i kekahi lāʻau lapaʻau.

ʻ instructionlelo aʻo Forsig

Nā palapala ʻano:
pani ʻ -lelo ʻlelo

Hōʻike
Hoʻokahi ʻia kahi papa kiʻi ʻoniʻoni, 5 mg,
Mea waiwai:
dapagliflozin propanediol monoholate 6.150 mg, helu ʻia ma dapagliflosin 5 mg
Loaʻa: microcrystalline cellulose 85.725 mg, lōpihi anhydrous 25,000 mg, crospovidone 5,000 mg, silicon dioxide 1,875 mg, magnesium stearate 1,250 mg,
ʻ shelllelo pulupulu: Opadray® II ʻāpana 5,000 mg (kapila polyvinyl i hoʻokaʻawale ʻia i ka 2,000 mg, titanium dioxide 1,177 mg, macrogol 3350 1.010 mg, talc 0.740 mg, dye hao oxide yellow 0.073 mg).

Hoʻokahi pū ʻia nā papa kiʻi 10-pile i loaʻa:
Mea waiwai:
dapagliflosin propanediol monohala 12,30 mg, heluʻa ʻia me dapagliflosin 10 mg
Nā mea hoʻihoʻi: microcrystalline cellulose 171.45 mg, lōpihi anhydrous 50.00 mg, crospovidone 10.00 mg, silika dioxide 3.75 mg, magnesium stearate 2.50 mg,
ʻ shelllelo pulupulu: Opadray® II ʻono melemele 10.00 mg (polyvinyl ka ʻāpana ʻokoʻa i hoʻoneʻe a 4.00 mg, titanium dioxide 2.35 mg, macrogol 3350 2.02 mg, talc 1.48 mg, dye hao oxide yellow 0.15 mg) . ^ E Ha yM.

ʻO keʻano
5 mg papa ʻaina i ulana ʻia:
Hoʻokomo ʻia nā papa biconvex poepoe me kahi membrane kiʻi melemele, i kahakaha ʻia me "5" ma kekahi ʻaoʻao a me "1427" ma kēlā ʻaoʻao.
Nā papa hana ʻoniʻoni, 10 mg:
Ua hoʻopaʻa ʻia nā papa bosenvex Rhomboid me kahi membrane kiʻi melemele, ke kahakaha ʻia me "10" ma kahi ʻaoʻao a me "1428" ma kēlā ʻaoʻao.

ʻĀpana Pharmacotherapeutic
Ka hoʻohana maʻi hypoglycemic no ka hoʻohana waha - type 2 glucose transporter inhibitor

ʻĀkau ATX: A10BX09

ʻO nā waiwai Pharmacological
Nā hana hana i ka hana
ʻO Dapagliflozin kahi hanohano (pale paʻa (Ki) o 0.55 nM), kahi ʻano koho hoʻohuli ʻōpiopio 2 sodium glucose cotransporter inhibitor (SGLT2). Kahi ʻia ka SGLT2 i loko o ka pūpū a ʻaʻole i ʻike ʻia ma mua o 70 mau kino ʻokoʻa ʻē aʻe (me ka ate, ka ʻūlū, ke kino ʻona, ka kiko adipose, nā mea momona, ʻiliahi, a me ka lolo). ʻO SGLT2 ka mea nui e lawe ai i ka glucose reabsorption i loko o ka renal tubules. ʻO ka reabsorption o ka hanu ma loko o nā ʻōpū o nā maʻi i nā mea maʻi me ka diabetes mellitus type 2 (T2DM) i hoʻomau ʻia ma ka maʻi hyperglycemia. Ma ka hoʻokaʻawale ʻana i ka hoʻololi ʻana i ka maʻi o ka glucose, ua hōʻemi ʻo dapagliflozin i kāna reabsorption i loko o ka renal tubules, e alakaʻi ana i nā hōʻiliʻili o nā huaʻai e nā keiki. ʻO ka hopena o ka dapagliflozin kahi i emi iho o ka wikiwiki o ka glucose a ma hope o ka ʻai ʻana, a me ka hoʻoemi ʻana i ka neʻe o ka hemoglobin glycosylated i loko o nā mea maʻi me ka maʻi diabetes type 2.
Hōʻalo i nā glucose (hopena hopena o glucosuric) ma hope o ka lawe ʻana i ka hapa mua o ka lāʻau lapaʻau, hoʻomau mau no nā 24 mau hola a hoʻomau i ka hana o ka maʻi. ʻO ka nui o ka glucose i hoʻopuka ʻia e nā keiki ma muli o kēia hana e pili ana i ka neʻe o ka glucose i ke koko a ma ka pae o ka filtration glomerular (GFR). ʻAʻole ʻo Dapagliflozin e hoʻopili i ka hana maʻamau o ka glucose endogenous i ka pane i ka hypoglycemia. He kūʻokoʻa ka hopena o dapagliflozin o ka huna ʻana o ka insulin a me ka ʻike ʻana i ka insulin. I nā haʻawina loea ʻo Forsig ™, ua ʻike ʻia kahi hoʻomaikaʻi ʻana i ka hana beta-cell (hōʻike HOMA, hōʻike loiloi homeostasis).
ʻO ka hoʻopauʻana o ka glucose e nā huaʻai i hoʻokumu ʻia e dapagliflozin me ka nalo ʻana o ka nui o nā kalori a me kahi laʻa o ke kaupaona ʻana. Dapagliflozin inhibition o ka sodium glucose cotransport i hele pū me nā diuretic nāwaliwali a me nā hopena natriuretic transient.
ʻAʻohe hopena o Dapagliflozin i nā mea lawe ʻē aʻe o ka glucose e lawe ana i ka glucose i nā kiko peripheral a hōʻike hou ʻia aku ma mua o 1,400 mau manawa nui ka koho no SGLT2 ma mua o SGLT1, ka transporter intestinal nui kuleana no ka hoʻopio ʻana i ka glucose.

Lapaʻau lāʻau
Ma hope o ka lawe ʻana i ka dapagliflozin e nā limahana olakino a me nā mea maʻi me ka maʻi diabetes type 2, ua nānā ʻia kahi hoʻonui o ka glucose i hoʻopā ʻia e nā keiki. I ka lawe ʻana o dapagliflozin ma kahi o 10 mg / lā no 12 mau pule, i nā mea maʻi me T2DM, ma kahi o 70 g o ka maʻi pākahi i kēlā lā i hoʻopiʻi ʻia e nā keiki (e like me ka 280 kcal / lā). I ka poʻe maʻi me ka maʻi diabetes type 2 nāna i lawe iā dapagliflozin ma ke ʻano o 10 mg / lā no ka manawa lōʻihi (a hiki i 2 mau makahiki), mālama ka glucose i waho ma ke ʻano o ka hopena o ka maʻi.
Hōʻailona ka puka o ka glucose e nā keiki me dapagliflozin e alakaʻi i ka diuresis osmotic a me ka hoʻonui o ka waihona i ka urine. ʻO ka hoʻonui ʻana i ka nui o ka urine i nā mea maʻi me ka maʻi diabetes type 2 e lawe ana i ka dapagliflozin ma kahi maʻa o 10 mg / lā i mau no 12 mau pule a ua like i kahi o 375 ml / lā. ʻO ka hoʻonui pū ʻana i ka nui o ka urine i ukali pū ʻia me ka hoʻonui liʻiliʻi a me ka pinepine o ka hoʻonui ʻana o ka sodium e nā lāʻau, ʻaʻole i alakaʻi i kahi hoʻololi o ke kao o ka sodium i loko o ka serum koko.

Lapaʻau lāʻau
Hoʻopau
Ma hope o ka lawelawe waha, ua lawe koke ʻia ʻo dapagliflozin a paʻa i loko o ka ʻeha gastrointestinal a hiki ke lawe ʻia i ka wā ʻai a ma waho o ia. ʻO ka hiki ke kau o dapagliflozin i loko o ke koko koko (Stax) e loaʻa pinepine i loko o 2 mau hola ma hope o ka wikiwiki. ʻO nā waiwai o Cmax a me AUC (ʻo ka wahi ma lalo o ka cur-time kukū) e hoʻonui i ka pā i ka nui o nā dosis o dapagliflozin. ʻO ka bioavailability piha o dapagliflozin i ka wā i lawelawe ʻia ai i ka waha ma kahi o 10 mg o 78%. ʻO ka ʻai ʻana he hopena maʻalahi i ka lāʻau lapaʻau ʻo dapagliflozin i nā mea hana olakino maikaʻi. ʻO nā meaʻai momona nui i hoʻemi ʻia ka Stax o dapagliflozin e 50%, ua hoʻonui aku iā Ttah (manawa e hiki ai i ka plasma kiʻekiʻe) e pili ana i ka hola 1, akā ʻaʻole i hoʻopilikia ia ʻo AUC i hoʻohālikelike ʻia i ka hoʻokē ʻai. ʻAʻoleʻike nui kēia mau loli.
Kahele
ʻO Dapagliflozin kahi e 91% e pili ana i nā protein. I nā maʻi me nā maʻi like ʻole, no ka laʻana, me ka maʻi lēwa ʻole a he hepatic function, ʻaʻole i loli kēia hōʻailona.
Hāpai
ʻO Dapagliflozin kahi glucose i hoʻopili ʻia ka C me kahi aglycon i hoʻopili ʻia i ka glucose ma o ka lākona a carbon-carbon, e hōʻoia ai i kona kūpaʻa e kūʻē i ka glucosidases. ʻO ka awelika plasma hapalua-ola (T½) i nā limahana olakino he 12.9 mau hola ma hope o hoʻokahi dosis o dapagliflozin ma ke ʻano iki ma ke ʻano o ka 10 mg. Hoʻololi ʻia ka Dapagliflozin e hana i kahi metabolite hana ʻoi loa a dapagliflozin-3-O-glucuronide.
Ma hope o ka mālama waha ʻana o 50 mg o 14C-dapagliflozin, 61% o ka lāʻau i lawe ʻia ka metabolized to dapagliflozin-3-O-glucuronide, nona ka nui o nā radio radioactivity plasma (AUC0-12 mau hola) - ʻO nā huina no ka loli o nā lā no 39% o ka radioactivity plasma pau loa. ʻAʻoleʻoi aku nā pōkole o nā metabolites i koe hoʻokahi no ka 5% o ka nui o ka radioactivity plasma. ʻAiʻi aku ʻo Dapagliflozin-3-O-glucuronide a me nā metabolites ʻē aʻe i ka hopena pharmacological. Kūkū ʻia ʻo Dapagliflozin-3-O-glucuronide e ka enzyme uridine diphosphate glucuronosyl transferase 1A9 (UGT1A9), aia i loko o ka pūpū a me nā pepeha, a me Cenue cytochrome isoenzymes i liʻiliʻi i ka metabolism.
Leʻaleʻa
ʻO nā Dapagliflozin a me nā metabolites ua hoʻopili nui ʻia e nā keiki, a heʻuʻuku hoʻi ma lalo o 2% ua hoʻohuli ʻia. Ma hope o ka lawe ʻana he 50 mg o 14C-dapagliflozin, ua ʻike ʻia he 96% o ka radioactivity - 75% i ka urine a me 21% i nā feces. Ma kahi o 15% o ka radioactivity i loaʻa i nā feces i helu ʻia e dapagliflozin i loli ʻia.
ʻO ka pharmacokinetics i nā kūlana kulekele kūikawā
ʻO ka maʻi me ka hana renal impaired
Ma ka hoʻohālikelike (ʻoi aku ʻo AUC), ka ʻike olakino o ka dapagliflozin i loko o nā mea maʻi me ka diabetes type 2 a me ke ʻano ʻōlohelohe, maʻalahi a paʻakikī paha (e like me ka hoʻoholo ʻana ʻo Iohexol clearance) he 32%, 60%, a he 87% kiʻekiʻe ma mua o nā mea maʻi me ka maʻi type 2 a me ka hana maʻamau. ʻeha, kēlā me kēia ʻO ka nui o ka glucose i hoʻopuka ʻia e nā ʻōpū i ka lā i ka wā e lawe ai i ka dapagliflozin ma ka equilibrium i hilinaʻi ʻia i ka mokuahi o ka hana. I nā maʻi me ka maʻi diabetes type 2 a me ka hana maʻamau maʻamau, a me ka hōʻino ʻole ʻana a me ka ikaika ʻole ʻole, 85, 52, 18 a me 11 g o nā glucose ka mea i hoʻopili ʻia i kēlā me kēia lā. ʻAʻohe hoʻākaʻawale ʻana i ka paa ʻana o dapagliflozin i nā protein i loko o nā mea hana olakino olakino a me nā mea maʻi e hiki ʻole ai ke like me ka ʻano paʻakikī. ʻAʻole i ʻike ʻia inā pili ka hemodialysis i ka hoʻolaha ʻana o dapagliflozin.
ʻO nā mea maʻi me ka hana pūlima hemahema
I nā mea maʻi me ka maʻi hepatic haʻahaʻa a maʻalahi paha, nā pono awelika o Cmax a me AUC o dapagliflozin he 12% a me 36% ke kiʻekiʻe, keu, ke hoʻohālikelike ʻia me nā mea hana olakino olakino. ʻAʻole koʻikoʻi nā ʻokoʻa o kēia mau ʻokoʻa, no laila ʻo ka hoʻoponopono ʻana o ka dosis no ka dapagliflozin i nā mea maʻi me ka maʻi maʻalahi e hōʻemi ʻia i ka naʻau (e ʻike i ka ʻāpana "Dosage a me ka hoʻokele"). ʻO Cmax a me AUC o dapagliflozin he 40% a 67% kiʻekiʻe loa, kēlā, ke hoʻohālikelike ʻia me nā mea hana olakino maikaʻi.
Nā maʻi maʻi maʻi (> 65 mau makahiki)
ʻAʻole i loaʻa ka nui o ka maʻi i ka maʻi i loko o nā mea maʻi ma lalo o nā makahiki he 70 (inā ʻaʻole ʻaʻole i manaʻo ʻia nā mea ʻē aʻe ma mua o ka makahiki). Eia nō naʻe, hiki ke hoʻonui ʻia ka loaʻa i ka ʻike ma muli o ka emi ʻana o ka hana hana i pili i ka makahiki. ʻAʻole lawa i nā hōʻike no ka poʻe maʻi ma mua o nā makahiki he 70.
Kakauolelo
I nā wahine, ʻo ka awelika AUC ka waiwai ma ka 22% ʻoi aku ka nui ma mua o nā kāne.
Kāhea
ʻAʻole i ʻike ʻia nā ʻokoʻa koʻikoʻi o ka maʻi o ka ʻōnaehana ma waena o nā ʻelele o nā lāhui Caucasian, Negroid a me Mongoloid.
Kau ka paona
Ua hoʻomaopopo ʻia nā hiʻona haʻahaʻa me nā piʻi kino o ke kino. No laila, i nā mea maʻi me ka hoʻohaʻahaʻa kino kino, hiki ke hoʻomaopopo ʻia i kahi liʻiliʻi o ke hoʻolaha ʻana, a i nā mea maʻi me ka nui o ke kaumaha kino - he hōʻemi i ka hoʻolaha ʻana o dapagliflozin. Eia naʻe, ʻaʻole he koʻikoʻi nā hana a kēia mau ʻokoʻa.

Nā hōʻailona no ka hoʻohana ʻana
ʻO ka type 2 diabetes mellitus i ka hoʻohui i ka ʻai a me ka hana e hoʻomaikaʻi ai i ka mana glycemic i ka maikaʻi.
monotherapy
hoʻohui i nā metformin therapy i ka haʻalele ʻana i ka mālama glycemic kūpono i kēia hoʻomehana,
Hoʻomaka i ka hoʻohui ʻana me ka metformin, inā e aʻo ʻia kēia lāʻau.

Nā Hoʻohui
Hoʻonui ka naʻau pono pilikino i kekahi hapa o ka lāʻau.
ʻAno maʻi type 1.
Maʻi molaʻi.
ʻO ka hikiʻole o ka hōʻeha a me ka hōʻeha koʻikoʻi (GFR 65 mau makahiki)
ʻO nā hopena maikaʻiʻole e pili ana i ka hana renal impaired a i ʻole ka papaha ʻole i hōʻike ʻia ma ka 2.5% o nā mea maʻi e loaʻa ana iā dapagliflozin, a ma 1.1% o nā mea maʻi e loaʻa ana i ka placebo i ka hui o nā mea maʻi> 65 mau makahiki he nui (e nānā i ka ʻāpana "Kūlana Kūlana"). ʻO ka hopena maʻamau e pili ana i ka hana renal impaired i ka nui o ka piʻi ʻana o ka serum creatinine. ʻO ka hapanui o kēia mau hopena, he transient a hoʻololi mai. Ma waena o nā mea maʻi> 65 mau makahiki, ka emi ʻana o ka BCC, ka mea pinepine i hoʻopaʻa ʻia ma ka hypotension arterial, ua nānā ʻia ma ka 1.5% a me ka 0.4% o nā maʻi e lawe ana i nā dapagliflozin a me ka placebo, ma kēlā me kēia (ʻike i ka ʻāpana "Kūlana Kūlana").

Ke keu
Ka palekana a Dapagliflozin a hōʻoluʻolu maikaʻi ʻia e nā mea kōkua olakino me ke ʻano hoʻokahi no ka 500 mg (50 mau manawa i hoʻolako ʻia). Ua hoʻoholo ʻia ʻo Glucose i loko o ka urine ma hope o ka lawe ʻana i ka lāʻau (ma ka liʻiliʻi o 5 mau lā ma hope o ka lawe ʻana i ka momona o 500 mg), ʻoiai ʻaʻole ʻaʻohe mau maʻi o ka maʻi, hypotension, electrolyte imbalance, hopena nui i ka maʻi ma ke kikowaena QTc. ʻO ka ulu ʻana o hypoglycemia i like me ke alapine me ka pletebo. Ma nā haʻawina ma loko o nā limahana olakino a me nā mea maʻi me ka maʻi diabetes type 2 ka mea i lawe i ka lāʻau lapaʻau hoʻokahi ma kahi o nā dosis a hiki i 100 mg (10 mau manawa kiʻekiʻe ma mua o ka nui o ka paipai ʻia no nā wiki 2, ʻoi aku ka nui o ka ulu ʻana o ka hypoglycemia ma mua o ka placebo, a ʻaʻole i hilinaʻi ʻia me ka dosis . ^ E Ha yM. ʻO ka ulu ʻana o nā hanana pōʻino, ʻo ka dehydration a i ʻole hypotension arterial, ka like me ka lekiō i ka hui plasebo, me ka nui o nā loli e pili ana i ka nui o nā panina ana o ka laboratori, e komo pū ana ka serum o nā electrolytes a me nā biomarkers o ka hana o ka pūpū.
I ka hihia o kahi overdose, pono ia e hoʻokō i ka mālama mālama ʻana, i ka mālama ʻana i ke kūlana o ka mea maʻi. ʻO ke kūkole o dapagliflozin e hemodialysis i aʻo ʻia i aʻo ʻia.

Hoʻopili pū me nā lāʻau ʻē aʻe
Diuretics
Hiki i ka Dapagliflozin ke hoʻonui i ka hopena diuretic o ka thiazide a me ka "loop" diuretics a hoʻonui i ka hopena o ka dehydration a me ka hypotension arterial (e nānā i ka ʻāpana "Hoʻomaopopo kūikawā").
Hoʻohui ʻano lāʻau
ʻO ka metabolism o dapagliflozin e lawe nui ʻia ma o ka conjuration glucuronide ma lalo o ka mana o UGT1A9.
In in vitro Studies, dapagliflozin not inhibit the isoenzymes of the cytochrome P450 system CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and not induce the isoen. I kēia mea, ʻaʻole i manaʻo ʻia ka hopena o dapagliflozin ma ka huakaʻi metabola o nā lāʻau concomitant e ʻano nei e kēia mauenemena.
Ka hopena o nā lāʻau ʻē aʻe ma dapagliflozin
ʻO nā haʻawina o nā hana e pili ana i nā mea hana olakino olakino, ʻo ka hapanui, ka poʻe i lawe i ka pākahi hoʻokahi o ka lālani, hōʻike ʻia ka metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan a simvastatin, ʻaʻole i hoʻopilikia i ka pharmacokinetics o dapagliflosin. Ma hope o ka hoʻohana pū ʻana o dapagliflozin a me rifampicin, kahi mea hoʻomohala o nā ʻano mea hoʻouluola a me nā ʻenehana e hoʻokaʻawale i nā lāʻau lapaʻau, hōʻemi ʻia ka systemic (AUC) o dapagliflozin e ka 22%, i ka lilo ʻole o ka hopena koʻikoʻi i ka maʻi maʻamau o ka glucose i nā lā o ka glucose. ʻAʻole ia e kuhikuhi i ka hoʻoponopono o ka lāʻau. ʻAʻole hiki ke manaʻo ʻia kahi hopena nui o ka klinikino i ka wā e hoʻohana ʻia me nā inducers ʻē aʻe (e.g. carbamazepine, phenytoin, phenobarbital).
Ma hope o ka hoʻohana pono ʻana o ka dapagliflozin me ka waikawa mefenamic (UGT1A9 inhibitor), kahi 55% i hoʻonui ʻia i ka hoʻopalike ʻana o nā dapagliflozin i ʻike ʻia, akā me ka loaʻa ʻole o ka hopena nui o ka maʻi ma ka lālaha o nā lālani o ka glucose e nā keiki. ʻAʻole ia e kuhikuhi i ka hoʻoponopono o ka lāʻau.
ʻO ka hopena o dapagliflozin i nā lāʻau lapaʻau ʻē aʻe
Ma nā haʻawina o nā pili i pili i nā mea hana olakino, ʻoiai ke lawe nei i ka pā hoʻokahi o ka lāʻau, ʻo ka dapagliflozin, ʻaʻole i hoʻopilikia i ka pharmacokinetics o metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (substrate of Varifarf, a i ʻole. isoenzyme CYP2C9), a i ʻole ma ka hopena anticoagulant, loiloi ʻia e ka International Normalized Ratio (MHO). ʻO ka hoʻohana ʻana i hoʻokahi pākahi o dapagliflozin 20 mg a me simvastatin (kahi papa o ka isoenzyme CYP3A4) hopena i ka hoʻonui ʻana i ka 19% i ka simvastatin AUC a me kahi 31% simvastatin acid AUC. ʻAʻole i manaʻo nui ʻia ka hoʻonui ʻana i ka simvastatin a me ka waikawa simvastatin i kahi nui koʻikoʻi.
ʻO nāʻoihana ʻē aʻe
ʻO nā hopena e pili ana i ka uahi ʻai, ka meaʻai, nā mea kanu lāʻau, a me ka hoʻohana ʻana i ka waiʻona ma ka lāʻau lapaʻau ʻo dapagliflozin ʻaʻole i aʻo ʻia.

Nā ʻōlelo kikoʻī
Hoʻohana i ka mea maʻi me ka hana renal impaired
Hoʻokomo ka hopena o dapagliflozin i ka hana waha, a ua hōʻemi ʻia kēia hana hoʻomanawanui i ka poʻe maʻi me ka hiki ʻole o ka renal moderate a i ʻole paha i hele i loko o nā mea maʻi me nā maʻi o ka maʻi haki (e nānā i ka ʻāpana "Dosage and Administration"). Ma waena o nā mea maʻi me ka haʻalulu māmā o ka maʻi (CC 65 mau makahiki, he nui ka nui o nā poʻe e loaʻa ana i ka dapagliflozin i hoʻomohala i nā hopena kūpono ʻole e pili ana i ka hana ʻana a hope ʻole i hoʻohālikelike ʻia i ka plasebo. serum creatinine concentrations, ʻo ka hapanui o nā hihia he transient a hoʻololi ʻia (e ʻike i ka ʻāpana "ʻaoʻao ʻaoʻao").
I nā poʻe maʻi elemakule, ʻoi aku ka nui o ka hōʻemi o ka hōʻemi i loko o ka BCC, a ʻoi aku ka nui o nā diuretics. Ma waena o nā mea maʻi> 65 mau makahiki, ʻo ka nui o nā mea maʻi e loaʻa ana iā dapagliflozin e loaʻa nā hopena e pili ana i ka hoʻemi ʻana i ka BCC (e nānā i ka ʻāpana "ʻaoʻao hopena").
Loaʻa ka ʻike no ka hoʻohana ʻana i ka lāʻau lapaʻau ma nā mea maʻi i nā makahiki he 75 a keu paha. Ua hoʻohālikelike ʻia e hoʻomaka i ka ʻoihana dapagliflozin i kēia heluna (e ʻike i nā ʻāpana "Dosage and Administration" a me "Pharmacokinetics").
Hoʻopau ʻole nā ​​puʻuwai naʻau
ʻO ka ʻike me ka lāʻau lapaʻau i nā mea maʻi me ka mālama ʻole o ka papa o ka papa hana I-II e like me ka helu ʻana o NYHA i palena, a i nā hōʻike kulana, ʻaʻole i hoʻohana ʻia nā dapagliflozin i nā maʻi me ka puʻuwai puʻuwai hōʻino o ka papa hana III-IV e like me NYHA.
Hoʻonui ka hematocrit
Ke hoʻohana nei iā dapagliflozin, ua nānā ʻia ka nui o ka hematocrit (e nānā i ka ʻāpana "ʻaoʻao ʻaoʻao"), a no laila e mālama pono ʻia ka poʻe maʻi i nā maʻi me ka hematocrit i hoʻonui ʻia.
ʻO ka loiloi o nā hopena hōʻike i ka urine
Ma muli o ka hiki o ka hana o ka lāʻau lapaʻau, e kūpono nā hopena o ka urine mo ka glucose i nā mea maʻi e lawe ana i ka Forsig ™.

Hoʻopilikia i ka hiki ke hoʻokau i nā kaʻa a me nā māka
ʻO nā haʻawina e aʻo ai i ka hopena o dapagliflozin ma ke hiki ke lawe i nā kaʻa a ʻaʻole i lawe ʻia nā hana.

E hoʻokuʻu i ke ʻano
ʻO nā papa pili kiʻi, 5 mg, 10 mg.
14 papa i loko o kahi palaki pōpoki alumini, 2 a i ʻole 4 mau kohu i loko o kahi pahu pahu me nā kauoha no ka hoʻohana ʻana, a he 10 mau papa i loko o ka blil foil alumunium perforated, 3 a 9 paha nā bl blurred i loko o ka pahu pepa me nā ʻōlelo i hoʻohana ʻia.
Hoʻopili ʻia nā wahi ākea o ka pahu kāpeka me nā mea hoʻomoʻa ʻole ʻelua i hoʻonohonoho ʻia, kahi kala melemele i hoʻohana ʻia ma ka ʻaoʻao waena o kēlā me kēia kikoʻī, kaupalena ʻia e nā laina waimaka.

ʻO ka lā kau
3 mau makahiki
Mai hoʻohana ma hope o ka lā pau pau i hōʻike ʻia ma ka pahu.

Nā kūlana mālama
Ma ke ana wela ʻaʻole 30% C, i nā wahi hiki ʻole i nā keiki.
E mālama i nā keiki.

Nā ʻōkole Holiday
Ma ke kumu.

Mea hana
ʻO Bristol Myers Squibb Manufaking Company, Puerto Rico
Alanui 3, Km. 77.5, PO Box 609, Humacao, PR-00791, Puerto Rico
ʻO Bristol-Myers Squibb Manufacturing Company
Alanui 3, Km 77.5, Pahuaka 609, Humacao, PR-00791, Puerto Rico

‘O ka inoa a me ka helu o ke kuleana loea i kākau ʻia ai kona inoa inoa kau inoa
ʻO Bristol Myers Squibb Company, USA
345, Ke Alakai Avenue, New York, NY, USA
ʻO Bristol-Myers Squibb Company, USA
345, Ke Alanui Park, New York, USA

Nā kuʻina o ka lāʻau Forsig

ʻOi like ka analogi mai ka palena o 1908 mau rubles.

ʻO Jardins kahi lāʻau lapaʻau haole no ka mālama ʻana i nā maʻi maʻi 2. ʻO Empagliflozin i ka nui o 25 mg no kēlā me kēia papa e hana nei ka mea ikaika wale nō. ʻO Jardins ka contraindications a me nā mea ʻaeʻī o nā makahiki, no laila e kamaʻilio me kāu kauka ma mua o ka hoʻomaka ʻana o ka mālama ʻana.

ʻOi like ka analogi mai ka makahiki 1967 mau rubles.

Mea Hana: Novo Nordisk (Denmark)
Kuhi puka:

• ʻLelo. 1 mg, 30 pcs., Kumukūʻai mai 175 mau rubles
• ʻLelo. 2 mg, 30 pcs., Kumukūʻai mai 219 mau rubles

ʻO NovoNorm kahi papa papaʻaina mai nā hui like ʻole, akā me nā ʻano hana like ʻole. Hoʻohana ʻia ka Repaglinide ma aneʻi ma kahi helu o ka 0.5 a hiki i ka 2 mg. Hoʻohālikelike nā ʻōkuhi no ke kuhikuhi ʻana, akā ʻokoʻa nā contraindications ma muli o nā DV i nā papa, no laila e heluhelu pono i nā ʻōkuhi a nīnau aku i kāu kauka.

ʻOi like ka analogi mai ka palena o 1908 mau rubles.

Mea Hana: Akrikhin (Lūkia)
Kuhi puka:

• ʻLelo. 1 mg, 30 pcs., Kumukūʻai mai 234 mau rubles
• ʻLelo. 2 mg, 30 pcs., Kumukūʻai mai 219 mau rubles

ʻO Novo Nordisk (Danemaka) NovoNorm kahi papa papa ʻaina mai ka hui like ʻole o ka ʻohana, akā me kahi ʻano like ʻole. Hoʻohana ʻia ka Repaglinide ma aneʻi ma kahi helu o ka 0.5 a hiki i ka 2 mg. Hoʻohālikelike nā ʻōkuhi no ke kuhikuhi ʻana, akā ʻokoʻa nā contraindications ma muli o nā DV i nā papa, no laila e heluhelu pono i nā ʻōkuhi a nīnau aku i kāu kauka.

Ua ʻoi aku ka uku o ka analogue mai ka 311 mau rubles.

Mea Hana: No ka huahua
Kuhi puka:

• ʻLelo. p / obol. 100 mg, 30 pcs., Kumukūʻai mai 2453 mau rubles
• ʻLelo. 2 mg, 30 pcs., Kumukūʻai mai 219 mau rubles

ʻO Novo Nordisk (Denemaka) NovoNorm kahi mea pono no ka Forsigi. ʻO ka mea hana e like me ka lāʻau lapaʻau ka repaglinide. ʻO ka lāʻau lapaʻau i loko o 30 mau minuke e hoʻonui i ka hoʻoliʻi ʻana o ka insulin i ke koko. Ma muli o ka nele o nā ʻike i nā noi i hoʻopaʻa ʻia ma ka palekana o ka lāʻau a me ka hoʻohana pono ʻana i nā papa i loko o nā ʻōpiopio o nā keiki, ʻaʻole ia he mea i hoʻohana i ka lāʻau no nā keiki ma lalo o ka makahiki 18 makahiki. I ke ʻano o nā hopena maikaʻiʻole, nā maʻi a me nā ʻeha o ka ʻōpū e hele pinepine ai.

Loaʻa nā Pūnaewele Hoʻoulu Forsigi

NovoNorm (mau papaʻaina) Rating: 152

ʻOi like ka analogi mai ka makahiki 1967 mau rubles.

ʻO NovoNorm kahi mea pono kūpono no Forsigi. ʻO ka mea hana e like me ka lāʻau lapaʻau ka repaglinide. ʻO ka lāʻau lapaʻau i loko o 30 mau minuke e hoʻonui i ka hoʻoliʻi ʻana o ka insulin i ke koko. Ma muli o ka nele o nā ʻike i nā noi i hoʻopaʻa ʻia ma ka palekana o ka lāʻau a me ka hoʻohana pono ʻana i nā papa i loko o nā ʻōpiopio o nā keiki, ʻaʻole ia he mea i hoʻohana i ka lāʻau no nā keiki ma lalo o ka makahiki 18 mau makahiki. I ke ʻano o nā hopena maikaʻiʻole, nā maʻi a me nā ʻeha o ka ʻōpū e hele pinepine ai.

ʻOi like ka analogi mai ka palena o 1908 mau rubles.

ʻO Jardins kahi papa papa e hoʻomākaukau ai i nā maʻi maʻi 2. ʻO ka mea nui o ka lāʻau lapaʻau he empagliflozin. Lawe ʻia ka lāʻau lapaʻau me ka ʻole o ka huki ʻana ma mua o ka ʻai, a i ka wā o ke komo ʻana o ka meaʻai, inā nalo nā lāʻau lapaʻau ʻole - ʻaʻohe pono e pālua i ka dosage no ke ʻano hou. ʻAʻole i ʻike ʻia a pehea ka hopena o kēia lāʻau lapaʻau a hiki ʻole ke lawe ʻia i ka wā o ka ʻōpū.

Diagninide (nā papa) Rating: 85 Top

ʻOi like ka analogue mai ka 1908 mau rubles.

ʻO Diagninide kahi mea laikini hypoglycemic agent, ke loaʻa nei ka repaglinide. Inā ʻaʻole kōkua kaʻai haʻahaʻa a me ka hoʻonaʻauao kino i ka mālama pono ʻana i ke kōpaʻa koko, a laila lawe wale i ka lāʻau. No nā poʻe kaʻa a me nā kānaka me ka ʻoihana e koi nui ana i ka nānā - me ka makaʻala nui ʻoe e pono e lawe i kahi diagninid. Inā hele nā ​​maʻi i nā palaka a i ʻole nā ​​hana o ka pūpū, mālama pono ʻia ka lāʻau lapaʻau.

Invokana (nā papa) Rating: 99 Top

Ua ʻoi aku ka uku o ka analogue mai ka 311 mau rubles.

Invokana - nā ʻāpana, nā like me nā capsules i ka pūpū, ua kahakaha ʻia me CFZ. ʻO Canagliflozin ka mea ikaika o kēia lāʻau lapaʻau. No ka lilo ʻo Invokana i kahi ʻano hou o ka poʻe hypoglycemic a hāʻawi i ka hoʻomaikaʻi maikaʻi ʻana no nā poʻe maʻi me ka maʻi maʻi. Ua kuhikuhi ʻia kēia lāʻau lapaʻau no ka mālama ʻana i nā maʻi me ka maʻi maʻi type 2.